Research and Markets: Antibacterials: Market Forecast - Detailed Ten-Year Sales Forecasts for Marketed Antibacterial Drugs

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Antibacterials: Market Forecast" directory to their offering.

Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as generic erosion of market leaders and increased competition between new hospital drugs will trigger a decline in sales of branded antibacterials. While there is a lack of innovation with regards to new community drugs, the hospital sector will remain the only notable source of growth.

Features and benefits

  • Detailed ten-year sales forecasts for marketed antibacterial drugs in each of the seven major markets
  • Analysis of the antibacterials market across the US, Japan, France, Italy, Germany, Spain and the UK


  • Over the next decade, genericization of key brands will drive a significant decline in market value, contributing to a loss of revenues of $3.2bn from Levaquin/Cravit/Tavanic, Zosyn/Tazocin, and Zyvox alone by 2019. Combined with growing resistance, this will cause increasing market fragmentation and reduce the potential for blockbuster sales.
  • The late-stage pipeline, much of which is targeting MRSA, will generate revenues totaling nearly $2.0bn by 2019. However, Datamonitor predicts that this upside will be insufficient to offset the decline caused by genericization, and total seven major market sales will fall from $19.6bn in 2009 to $16.4bn in 2019, with a CAGR of -1.8%.

Your key questions answered

  • Assess and quantify the market opportunity for antibacterials, from generics to high-priced hospital brands.
  • Assess the impact of key issues affecting the antibacterials market; generic erosion and growing levels of resistance

For more information visit

Source: Datamonitor


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Pharmaceutical